IPO listing: bank holding company FVCBankcorp (FVCB)

FVCBankcorp, Inc. (NASDAQ: FVCB) was founded in 2007 and is headquartered in Fairfax, Virginia, USA, with 98 full-time employees (6/30/2018). It is a bank holding company. Through its wholly-owned subsidiaries and community banks—— FVCbank serves the banking needs of commercial enterprises, non-profit organizations, professional service entities and their respective owners and employees located in the metropolitan area of ​​Washington, DC and Northern Virginia.


FVCBankcorp (FVCB):

FVCbank believes that the size, growth, and growing economic diversity of Washington, DC, the metropolitan area, and Northern Virginia, coupled with the company’s banking strategy, provide us with excellent opportunities for long-term sustainable growth. The company’s goal is to take full advantage of market opportunities while maintaining a disciplined and conservative credit underwriting culture. FVCBankcorp focuses on providing highly interactive and responsive customer service to enable it to compete in the market, meet and exceed customer needs. Since starting its banking business in 2007, FVCBankcorp has experienced significant organic growth.

As of June 30, 2018, FVCBankcorp has total assets of US$1.14 billion, total loans of US$955.6 million, total deposits of US$1.01 billion, and total shareholder equity of US$104 million. FVCBankcorp recently announced the acquisition of Colombo Bank, a bank headquartered in Rockville, Maryland with a total qualification value of US$191 million. The company expects that the acquisition will be completed after the completion of the fourth quarter of 2018.

As of June 30, 2018, FVCBankcorp has 6 full-service banks in Washington, DC, Metropolitan and Northern Virginia.

FVCBankcorp (FVCB) investment:

FVCBankcorp, Inc. (NASDAQ:FVCB) submitted its IPO prospectus on 8/20/2018, and plans to land on Nasdaq on 9/14/2018. The issue price is $19.00-$21.00, 1.8 million shares are issued, Sandler O’Neill + Partners/ Raymond James joint underwriting.

Notify of
Inline Feedbacks
View all Intels

Clinical phase biopharmaceutical company: Anavex Life Sciences (AVXL) (2006)

FMCG company: Unilever Plc (UL) (1885)